ArticleMediterranean journal of rheumatology2025
Zinc, Copper, and Manganese Supplementations in Rheumatic Disease: A Narrative Review.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic potential of zinc supplementation in rheumatoid arthritis: clinical evidence, molecular mechanisms, and formulation-specific effects.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
- The Role of Metals and Trace Elements in the Pathogenesis of Osteoarthritis and Other Rheumatic Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trace elements, including zinc (Zn), copper (Cu), and manganese (Mn), play crucial roles in various biological functions, particularly in oxidative stress regulation and immune response. Their potential involvement in rheumatic diseases has been suggested, with evidence indicating altered levels of these elements in conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). However, the efficacy of supplementation remains unclear. Objective: This narrative review aims to evaluate the available evidence on Zn, Cu, and Mn supplementation in patients with rheumatic diseases. Methods: A comprehensive literature search was conducted in PubMed, Scielo, and LILACS databases for studies published from 1965 to April 2024. The search followed PRISMA guidelines and included randomised controlled trials (RCTs) and observational studies investigating Zn, Cu, or Mn supplementation in rheumatic diseases. Results: A total of four studies met the inclusion criteria, focusing on Zn and Cu supplementation. No studies on Mn supplementation were identified. Among the included studies, two evaluated Zn supplementation in RA and Behçet's disease, while two assessed Cu supplementation in RA and SLE. The mean participant age ranged from 35 to 54.3 years, with female predominance (28% to 89%). Follow-up durations varied from 4 to 24 weeks. Zn supplementation demonstrated clinical and immunological benefits, including reduced disease activity in Behçet's disease and improved inflammatory markers in RA. Conversely, Cu supplementation did not show significant therapeutic effects. Reported side effects were mild and primarily gastrointestinal, occurring in 4% to 33% of participants. Conclusion: Zn supplementation appears beneficial in certain rheumatic diseases, particularly in RA and Behçet's disease, while Cu supplementation lacks significant therapeutic effects. Further high-quality RCTs are needed to establish definitive recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.